Rubius Therapeutics developed our proprietary RED PLATFORM® to generate red blood cells and genetically engineer them into a new class of cellular medicines, called Red Cell Therapeutics™ (RCTs). Our RED PLATFORM harnesses both the unique properties of red blood cells and the creative potential of genetic engineering to deliver on the promise of cellular therapy and transform how diseases are treated.
Red Cell Therapeutics are engineered to express biotherapeutic proteins within or on their cell surface to create highly selective, potent and allogeneic cellular medicines aimed at treating a range of diseases. They can potentially be used to kill tumors in cancer and regulate the immune system for the treatment of autoimmune diseases.
We are currently enrolling patients in a Phase 1/2 clinical trial of RTX-240; the trial has two separate Phase 1 arms: an ongoing monotherapy dose escalation arm in adults with relapsed/refractory or locally advanced solid tumors and a combination therapy dose escalation arm with pembrolizumab in adults with relapsed/refractory or locally advanced solid tumors. The combination arm has been expanded to focus on patients with non-small cell lung cancer and renal cell carcinoma. We are also enrolling patients in a Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer.